Back to search
FDAFDA · Food and drugs·Recall number D-0733-2021

Amikacin Sulfate Injection USP 1 gram/4mL (250mg/ML), 4 mL single-dose vials, Rx only, Teva Pharmaceuticals USA Inc. North Wales, PA 19454, NDC 0703-9040-01

Published August 25, 2021 · Recall initiated: July 29, 2021

Summary

FDA records drug Class II recall D-0733-2021, published August 25, 2021 and initiated July 29, 2021. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 4,712 vials; Lot: Lot #: 31329243B, exp. date 05/2022. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Product was distributed Nationwide, including Puerto Rico.
Lot
Lot #: 31329243B, exp. date 05/2022
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Amikacin Sulfate Injection USP 1 gram/4mL (250mg/ML), 4 mL single-dose vials, Rx only, Teva Pharmaceuticals USA Inc. North Wales, PA 19454, NDC 0703-9040-01 recalled?

Yes. FDA published recall D-0733-2021 on August 25, 2021. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter